Concern over pricy medication 'just headlines'
March 24, 2014 at 13:50 PM EDT
Gilead Sciences' high-priced drug Sovaldi is under lawmakers' scrutiny. But biotech analyst Christopher Raymond of R.W. Baird says there's a bigger problem.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.